Asset Details
Do you wish to reserve the book?
吉非替尼治疗32例肺腺癌脑转移的临床经验
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
吉非替尼治疗32例肺腺癌脑转移的临床经验
Do you wish to request the book?
吉非替尼治疗32例肺腺癌脑转移的临床经验
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
吉非替尼治疗32例肺腺癌脑转移的临床经验
2015
Overview
背景与目的脑转移是晚期非小细胞肺癌（non—small cell lung cancer,NSCLC）常见的转移部位，预后欠佳。吉非替尼是一种表皮生长因子受体（epithelial growth factor receptor,EGFR）酪氨酸激酶抑制剂，用于治疗晚期NSCLC。本研究旨在探讨吉非替尼治疗肺腺癌脑转移的疗效及毒副反应。方法回顾性分析32例肺腺癌脑转移患者的临床资料，所有患者均口服吉非替尼250mgq，直到疾病进展或发生不可耐受的毒副反应。结果全组32例患者的中位生存时间（median overall survival，mOS）和中位无进展生存时间（median progression-free survival，mPFS）分别为24．7个月和11．2个月，有效率（response rate,RK）和疾病控制率（disease control rate，DCR）分别为62．5％和93．8％。吉非替尼用于初治患者的mOS和mPFS分别为35．6个月和11．3个月，RR和DCR分别为75．0％和100．0％。吉非替尼用于复治患者的mOS和mPFS分别为18．6个月和6．7个月，RR和DcR分别为50．O％和83．396。EGFR敏感性突变患者的mOS和mPFS分别为24．8个月和10．8个月，RR和DCR分别为75．0％和100．0％。EGFR突变状态不明患者的mOS和mPFS分别为3S．6个月和12．3个月，蝴DcR分别为53．3％和86．7％。全组患者耐受性好，未观察到严重毒副反应。常见的毒副反应包括：皮疹15例（46．9％）、腹泻7例（21．9％）、口腔溃疡1例（3．1％）。结论吉非替尼对肺腺癌脑转移患者有效率较高且耐受性好，可以作为肺腺癌脑转移患者的一种治疗选择。
We currently cannot retrieve any items related to this title. Kindly check back at a later time.